[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aggressive-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aggressive-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641182","predictive-value-of-tumor-microenvironment-petct-for-response-and-prognosis-in-aggressive-lymphoma-a-multicenter-study-100641182",false,"NCT07657494","Predictive Value of Tumor Microenvironment PET\u002FCT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study","The Predictive Value of Tumor Microenvironment PET\u002FCT Imaging for Treatment Response and Prognosis in Aggressive Lymphoma: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Histologically confirmed aggressive lymphoma.\n* Baseline PET\u002FCT showing moderate to high FDG uptake in lymphoma lesions.\n* No previous history of malignant tumors.\n* No significant cardiac, hepatic, or renal dysfunction.\n* Expected survival of at least 6 months and ability to complete follow-up.\n\nExclusion Criteria:\n\n* Low FDG uptake on baseline PET\u002FCT.\n* Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.\n* Active or uncontrolled chronic inflammation or infection.\n* Uncontrolled diabetes mellitus.\n* Incomplete clinical data or loss to follow-up.\n* Refusal to sign the informed consent form.\n* Inability to lie supine for 30 minutes.","ALL","18 Years",{"count":19,"type":20},94,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicenter study aims to evaluate the predictive value of tumor microenvironment PET\u002FCT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET\u002FCT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET\u002FCT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.",[26],"Aggressive Lymphoma","RECRUITING","2026-06-14",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2024-07-11",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":61,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":39},"100553360","early-palliative-care-for-patients-with-multiple-myeloma-and-aggressive-lymphoma-100553360","NCT06485076","Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma","Phase II Feasibility Study of Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma","EPC-MM+L","Patient eligibility criteria:\n\nInclusion criteria:\n\n(i) Age ≥18 years; (ii) A new diagnosis of multiple myeloma or at progression of disease necessitating a change in treatment plan, or relapsed\u002Frefractory aggressive B cell lymphoma after one prior line of therapy; (iii) Eastern Cooperative Oncology Group (ECOG) performance status 0-3; (iv) Willingness to complete symptom screening; and (v) At least one ESAS-r-plus symptom scored at ≥3 at time of recruitment.\n\nExclusion criteria:\n\n(i) Insufficient English literacy to complete study procedures; (ii) Hematologist-determined poor cognitive status; (iii) Current palliative care team involvement at PM or elsewhere; and (iv) Not receiving ongoing follow up with malignant hematology team at PM.\n\nCaregiver eligibility criteria:\n\nInclusion criteria:\n\n(i) Age ≥18 years; (ii) Caregiver of a patient with relapsed B cell lymphoma; and (iii) Willing to attend at least 1 PCC visit with the patient.\n\nExclusion criteria:\n\n(i) Insufficient verbal and\u002For written English literacy to complete study procedures; or (ii) Patient not participating in study.\n\nHealthcare provider eligibility criteria:\n\nInclusion criteria:\n\n(i) Specialized staff physician, fellow, clinical nurse specialist, or clinic nurse from the outpatient malignant hematology team or palliative care team at PM working clinically with patients with multiple myeloma; and (ii) Working in their clinical area for at least 12 months.",true,{"count":50,"type":20},144,[23],"Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of life in patients with solid tumours (e.g. lung, breast or gynecological cancers), but has not been explored among patients with blood cancers to date.\n\nThe goal of this clinical trial is to a brief early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma and their caregivers (lymphoma only) attending the Princess Margaret Cancer Centre. The main goals of the study are:\n\n* To see if it is possible to apply the early palliative care intervention for patients with multiple myeloma and aggressive lymphoma and their caregivers (lymphoma only)\n* To see if this early palliative care intervention works well for these patients and caregivers\n* To compare patient and caregiver experiences with early palliative care and usual care\n* To explore perceptions and experiences of providing palliative care among healthcare providers involved in the care of these patients and caregivers.\n\nPatients, and their respective caregivers if participating, will be randomly assigned to one of two groups: one group will receive early palliative care in addition to usual care from their blood cancer doctor, and the other group will receive usual care from their blood cancer doctor only. All participants will be asked to fill out questionnaires about their quality of life, symptom burden, mood, and satisfaction with care throughout the study. Researchers will compare the results between the two groups to see if there are any improvements in quality of life for the patients who received early palliative care and their caregivers.\n\nSome patients and caregivers will be asked to take part in interviews at the end of the trial to answer questions about their experience taking part in the study. Some healthcare providers who care for these patients will also be asked to take part in interviews at the end of the trial to describe their perceptions and experiences of providing palliative care.\n\nThe researchers will use the results of this study to guide in the development of a larger clinical trial.",[54,55,56,57,58,59,60,26],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory","Multiple Myeloma Stage III","Multiple Myeloma Progression","Multiple Myeloma","B Cell Lymphoma","Lymphoma, B-Cell",[62,63,64,65,66],"early palliative care","multiple myeloma","quality of life","symptom management","aggressive lymphoma","2025-11-25",{"date":69,"type":31},"2025-12-03",{"date":71,"type":31},"2024-07-18",{"date":73,"type":20},"2027-06",{"name":75,"class":38},"University Health Network, Toronto"]